Notable companies
The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).
Industry description
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Market Cap
The average market capitalization across the Biotechnology Industry is 2.25B. The market cap for tickers in the group ranges from 31.65 to 323.27B. NONOF holds the highest valuation in this group at 323.27B. The lowest valued company is CYCCP at 31.65.
High and low price notable news
The average weekly price growth across all stocks in the Biotechnology Industry was 4%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was -2%. IMNN experienced the highest price growth at 281%, while POLBF experienced the biggest fall at -64%.
Volume
The average weekly volume growth across all stocks in the Biotechnology Industry was 91%. For the same stocks of the Industry, the average monthly volume growth was 130% and the average quarterly volume growth was 325%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 65
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)